Search Results
Oct 14, 2025, 02:19 ET Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
inhibiting mobilization of immunosuppressive cells into tumors. On the other hand, GNTbm-TKI + GNTbm-38 combined with anti-PD-1/VEGF bispecific antibodies in a humanized B-PD-1/PD-L1/VEGFA mouse model also greatly improved anti-cancer with a strong synergistic effect. GNTbm-TKI
More news about: Great Novel Therapeutics Biotech & Medicals Corporation
Oct 14, 2025, 00:48 ET BenQ Launches New Monitors for Mac Users and Creative Professionals
https://www.benq.com/en-us/monitor/professional/pd2770u.html. Experience BenQ at Adobe MAX 2025Attendees can see the new MA270UP and PD2770U, along with the PD2730S (5K), SW321C, and PV3200U in action
More news about: BenQ
Oct 13, 2025, 12:10 ET Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 09:00 ET iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson's disease (PD). Recently, NouvNeu001 Phase I clinical data were presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS).
More news about: iRegene therapeutics
Oct 13, 2025, 08:30 ET Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents
More news about: Actinium Pharmaceuticals, Inc.
Oct 13, 2025, 07:00 ET Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
companies with differentiated Fc-reduced TIGIT programs, including two oral presentations from Compugen's partner AstraZeneca with rilvegostomig- Fc reduced PD1/TIGIT bispecific, the TIGIT component of which is derived from Compugen's clinical stage, COM902. About Compugen
More news about: Compugen Ltd.
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
Translational PK/PD modelling of LY4170156, an antibody-drug conjugate linked to exatecan via a novel cleavable polysarcosine linker
More news about: Eli Lilly and Company
Oct 13, 2025, 02:07 ET Baseus Unveils EnerGeek GX11 4G MiFi Power Bank: World's First 20,000mAh, 67W Fast-Charging Power Bank with Integrated 4G Hotspot Connectivity
GX11 4G MiFi Power Bank combines high-speed charging with reliable connectivity for extended travel. Featuring USB-C and USB-A fast-charging ports with PD and QC protocol support, it delivers broad compatibility across laptops, tablets, smartphones, and other modern devices, and can charge up to three devices
More news about: BASEUS TECHNOLOGY (HK) CO, LIMITED
Oct 09, 2025, 16:15 ET Endo Announces Nine New and Modified Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting
Disease Peyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.1 It is estimated that PD can affect as many as 1 in 10 men in the U.S.,2 but
More news about: Endo USA, Inc.
Oct 09, 2025, 10:10 ET Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions
ADAPT-PD study was published in the Journal of the American Medical Association (JAMA) Neurology showing clinical effectiveness, long-term safety,
More news about: Medtronic plc
Oct 09, 2025, 08:22 ET Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
solid tumors via its differentiated mechanism. The drug not only induces stronger PD-1 internalization—reducing PD-1 receptor presence on T cells for rapid and potent immune activation [3]—but also minimizes PD-1-mediated recruitment of the co-stimulatory molecule CD28, thereby preserving CD28
More news about: Henlius
Oct 09, 2025, 08:04 ET Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in Canada
EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit
More news about: Bio-Thera Solutions, Ltd
Oct 09, 2025, 07:38 ET 開創無化療時代：全球首個H藥胃癌圍手術期III期臨床研究達到主要終點，支持提前申報上市
[3] Issafras H, et al. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS One. 2021;16(12):e0257972.
More news about: 復宏漢霖
Oct 08, 2025, 12:27 ET Rotary Air Preheaters Market Size to Reach USD 1.8 Billion by 2033, Growing at 5.2% CAGR from 2026-2033 - Market Research Intellect
Market Size By Application (Lung Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma, Head and Neck Cancers), By Product (PD-1 Inhibitors (Programmed Cell Death Protein 1), PD-L1 Inhibitors (Programmed Death-Ligand 1), CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein 4), Combination Therapies,
More news about: Market Research Intellect
Oct 08, 2025, 08:01 ET TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
R&D exploration of combining TTX-MC138 and seviprotimut-L technologies TTX-siPDL1, siRNA-based modulator of PD-L1 TTX-RIGA, RNA-based agonist of RIG-I TTX-siMYC, RNA-based inhibitor of c-MYC
More news about: TransCode Therapeutics, Inc.
Oct 08, 2025, 08:00 ET Biond Biologics Announces Initiation of a Phase 2 Study of BND-22 in Combination with anti-PD-1 therapy
announced the launch of a Phase 2 study of BND-22 (SAR444881) in combination with anti-PD-1 therapy in patients with locally advanced or metastatic NSCLC previously treated with immune-oncology (IO) therapies, and anti–PD-1/PD-L1 naïve patients with MSS-CRC or ovarian cancer (ClinicalTrials.gov Identifier:
More news about: Biond Biologics Ltd.
Oct 07, 2025, 17:50 ET Avanti Unveils Major Enhancements to Transform Professional Learning for Educators
Global PD Teams and
More news about: Solution Tree
Oct 07, 2025, 14:11 ET Circulogene Expands Solid Tumor Genomic Capabilities with Launch of OncoGenDx Tissue Assay
into all solid tumors. Designed to complement Circulogene's existing portfolio—including OncoGenLDx, the industry's only plasma-based test reporting PD-L1 expression, and LungLifeAI, a targeted solution for risk stratifying incidental lung nodules—the new assay reflects Circulogene's ongoing commitment
More news about: Circulogene
Oct 07, 2025, 11:51 ET WaveBreak Presents Human Brain Tissue Data Demonstrating Binding and Efficacy of Small Molecule WTX-607 Against Alpha-Synuclein Aggregates for Parkinson's Disease and Lewy Body Dementia
DiseaseOne million people in the U.S. and up to 10 million people worldwide are living with Parkinson's disease (PD). With nearly 90,000 people in the U.S. diagnosed each year, PD is the fastest-growing neurologic disease in the U.S. and is expected to affect 1.2 million people by 2030. The accumulation
More news about: WaveBreak
Oct 07, 2025, 08:30 ET Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
resistant, post-translationally modified forms of PD-L1. By binding PD-L1 and recruiting the cell's natural protein disposal machinery, NDL2 drives the breakdown and clearance of the modified PD-L1 across all cellular compartments. Targeting these resistant PD-L1 pools that antibody therapies cannot reach
More news about: Kazia Therapeutics Limited
Oct 07, 2025, 08:01 ET Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
the three patients.EV PD-L1: Decreases in the subset of large EVs carrying PD-L1 were observed in all three participants during the Hemopurifier treatment. Persistently elevated counts of EVs with PD-L1 have been associated with lack of response to anti-PD-1 agents.
More news about: Aethlon Medical, Inc.
Oct 07, 2025, 06:00 ET InsightRX Achieves 96.1 Performance Score in KLAS Spotlight as the First Precision Dosing AI Solution
next horizon is a future powered by InsightRX's upcoming agentic AI system. This next generation clinical decision support tool will bring together PK/PD modeling and simulation with broader sources of clinical context, including guidelines, institutional protocols, and pharmacogenomics. By collating and
More news about: InsightRX
Oct 07, 2025, 02:21 ET Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17
syngeneic animal models of cancer, the compound has shown promising potentiation of immune-modulating treatments in several cancer forms, including anti-PD1 checkpoint inhibitors in colon cancer (CT26) and standard of care (temozolomide and radiation) in glioblastoma (GL261). Pharmacokinetic studies of BEA-17
More news about: Beactica Therapeutics AB
Oct 07, 2025, 02:17 ET Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17
syngeneic animal models of cancer, the compound has shown promising potentiation of immune-modulating treatments in several cancer forms, including anti-PD1 checkpoint inhibitors in colon cancer (CT26) and standard of care (temozolomide and radiation) in glioblastoma (GL261). Pharmacokinetic studies of BEA-17
More news about: Beactica Therapeutics AB
Oct 06, 2025, 09:00 ET Clario and the University of Oxford's NeuroMetrology Lab Advance Parkinson's Disease Research with the Opal® Wearable Sensor System
falls, which represent a significant cause of disability and reduced quality of life in PD patients. Findings from Professor Antoniades' team demonstrate the high potential of movement analysis in PD research and pave the way for predictive and preventive healthcare. In a
More news about: Clario